October 4-8, 2017 | San Diego Convention Center
November 2-4 2017
Novoclem Therapeutics was created to develop nitric oxide solutions for cystic fibrosis and other respiratory diseases. It is initially focused on producing a treatment to reduce the incidence of severe bacterial lung infections in CF patients.
The technology is effective against both antibiotic-resistant Pseudomonas aeruginosa, which is present in the lungs of approximately 60 percent of patients with CF and Mycobacterium abscessus, a growing threat to CF patients.
The company anticipates submitting an Investigational New Drug application and initiating First-in-Human clinical trials in early 2018.